pm mfvt1
    • Main page
      • About journal
      • Articles. Working with contents
      • Editor-in-chief
      • Editorial Council
      • Editorial Board


      • For authors
      • Standards for formatting information
      • Reviewing
      • Politics editorial board
      • Ethics of journal publications


      • For advertisers
      • Subscription
      • About the Publishing House
      • Contact us
  • Predicting the course of chronic cardiac failure combined with chronic obstructive pulmonary disease

    Редактор | 2020, Original articles, Practical medicine part 18 №1. 2020 | 1 апреля, 2020

    V.M. GAZIZYANOVA, O.V. BULASHOVA, E.V. KHAZOVA, V.N. OSLOPOV

    Kazan State Medical University of the Ministry of Health of the Russian Federation, Kazan

      Contact:

    Gazizyanova V.M. ― PhD (medicine), Associate Professor of the Department of Propedeutic Internal Diseases named after S.S. Zimnitskiy

    Address: 49 Butlerov Str., Kazan, Russian Federation, 420012, e-mail: sunny.gazizyanova@list.ru

    Today multiple morbidity is characteristic for patients with chronic cardiac failure (CCF), which contributes to the course of the main and the accompanying disease and significantly worsens the prognosis, resulting in large social-economic losses.

    The objective is to research the yearly prognosis for CCF combined with chronic obstructive pulmonary disease.

    Material and methods. The research included 183 patients with CCF, of them 105 ‒ CCF combined with chronic obstructive pulmonary disease. All patients underwent the following examinations: walk test, scoring the clinical condition, external breathing function test with spirometry, standard echocardiography, life quality assessment.

    Results. Patients with CCF combined with chronic obstructive pulmonary disease (COPD) were characterized by high smoking rate, low quality of life and low tolerance to physical load. Cardiovascular death rate in CCF combined with COPD was 4.0%, not differing significantly from that in CCF without COPD ― 4.6%; myocardial infarction was 1.7 more frequent in CCF combined with COPD than in patients with CCF without COPD (16.8% and 10.8%); stroke was observed only in CCF combined with COPD (8.9%). Combined end point (all cardiovascular events) in comorbid pathology was 2.3 more frequent that in patients with CCF only (29.7% and 15.4%). Hospitalization due to acute decompensation of CCF was 2 times more frequent in the group with comorbid pathology (CCF and COPD), that without it (32.7% and 15.4%).

    Conclusion. The research results showed that chronic obstructive pulmonary disease contributes a lot to the clinical variant of CCF, which significantly aggravates the prognosis and requires an integral approach to the treatment tactics and stratification of the risk of undesired events.

    Key words: prognosis, chronic obstructive pulmonary disease, chronic heart failure.

    (For citation: Gazizyanova V.M., Bulashova O.V., Khazova E.V., Oslopov V.N. Predicting the course of chronic cardiac failure combined with chronic obstructive pulmonary disease. Practical medicine. 2020. Vol. 18, №1, P. 65-69)

    REFERENCES

    1. Demograficheskiy ezhegodnik Rossii 2012. Stat. sb. Rosstat [Demographic Yearbook of Russia 2012. Statistical Bulletin of Rosstat]. Moscow, 2013.
    2. Mareev V.Yu., Fomin I.V., Ageev F.T. Clinical recommendations OSSN — RKO — RNMOT Heart failure: chronic (CHF) and acute decompensated (ODSN). Diagnosis, prevention and treatment. Kardiologiya, 2018, no. 58 (S6), pp. 1-164 (in Russ.).
    3. Federal’naya programma “Khronicheskie obstruktivnye bolezni legkikh”, pod red. A.G. Chuchalina. 2-e izd., pererab. i dop. [The federal program «Chronic obstructive pulmonary disease». Ed. By A.G. Chuchalin. 2nd ed., revised. and add]. Moscow, 2004. P. 63.
    4. Rutten F.H., Cramer M.J., Grobbee D.E. et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur. Heart J, 2005, no. 26 (18), pp. 1887-94.
    5. Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet, 2007, no. 370 (9589), rr. 765-773.
    6. Anthonisen N.R., Skeans M.A., Wise R.A. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med, 2005, no. 142 (4), rr. 233-9.
    7. Holguin F., Folch E., Redd S.C. et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest, 2005, no. 128 (4), rr. 2005-2011.
    8. Fedotov P.A. Features of managing a patient with comorbid pathology: treatment of heart failure of ischemic genesis with carvedilol with concomitant COPD. Zemskiy vrach, 2012, no. 6 (17), pp. 31-37 (in Russ.).
    9. Rushton C.A., Satchithananda D.K., Jones P.W. Noncardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: a systematic review and meta-analysis. Int. Journal of Cardiology, 2015, no. 196, rr. 98-106.
    10. Canepa M., Temporelli P.L., Rossi A. et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure: data from the GISSI-HF Trial. Cardiology, 2017, no. 136 (2), rr. 128-137.
    11. Filatova Yu.I. Features of the prevalence and structure of arrhythmias in patients with chronic obstructive pulmonary disease. Molodoy uchenyy, 2014, no. 5, pp. 160-164 (in Russ.).
    12. Shugushev Kh.Kh., Gurizheva M.V., Vasilenko V.M. Supraventricular arrhythmias and high-resolution ECG in patients with chronic obstructive pulmonary disease with bronchodilator therapy. Rossiyskiy kardiologicheskiy zhurnal, 2010, no. 6 (86), pp. 40-44 (in Russ.).
    13. Buch P. et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur. Respir. J, 2003, no. 21, rr. 1012-1016.
    14. Bazdyrev E.D. et al. Osobennosti vedeniya patsientov s khronicheskoy obstruktivnoy bolezn’yu legkikh v sochetanii s serdechno-sosudistymi zabolevaniyami. Metodicheskie rekomendatsii dlya vrachey [Features of management of patients with chronic obstructive pulmonary disease in combination with cardiovascular diseases]. Kemerovo, 2012. P. 55.
    15. Rutten Frans H. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch. Internal. Med, 2010, 170 (10), pp. 880-887.
    16. Sin D.D., Wu L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest, 2005, no. 127, rr. 1952-1959.
    17. Shlyakhto E.V., Arutyunov G.P., Belenkov Yu.N. National guidelines for risk determination and prevention of sudden cardiac death. Klinicheskaya praktika, 2012, no. 4, 80 p. (in Russ.).
    18. Chuchalin A.G., Aysanov Z.R., Chikina S.Yu. et al. Federal clinical recommendations of the Russian respiratory society on the use of spirometry method. Pul’monologiya, 2014, no. 6, pp. 11-24 (in Russ.).

    Метки: 2020, chronic heart failure, chronic obstructive pulmonary disease, E.V. KHAZOVA, O.V. BULASHOVA, Practical medicine part 18 №1. 2020, prognosis, V.M. GAZIZYANOVA, V.N. OSLOPOV

    ‹ Fetal growth restriction: is it always hypotrophy of a newborn? Influence of urinary tract microbiota on premature rupture of membranes at term pregnancy ›
    • rus Версия на русском языке


      usa English version site


      Find loupe

      

    • PARTNERS

      пов  logonew
    «Для
    Practical medicine. Scientific and practical reviewed medical journal
    All rights reserved ©